A prospective, open-label, dose-escalating study of low molecular weight heparin during repeat vitrectomy for PVR and severe diabetic retinopathy

R. Gary Lane,J. Michael Jumper,Ma’an A. Nasir,Mathew W. MacCumber,Brooks W. McCuen

A prospective, open-label, dose-escalating study of low molecular weight heparin during repeat vitrectomy for PVR and severe diabetic retinopathy

2005

R. Gary Lane
J. Michael Jumper
Ma’an A. Nasir
Mathew W. MacCumber
Brooks W. McCuen

Background To determine the maximum tolerated dose (MTD) of enoxaparin, a low molecular weight heparin (LMWH) was used during repeat vitrectomy for rhegmatogenous retinal detachment with proliferative vitreoretinopathy (PVR) and severe diabetic retinopathy.

Keywords:

Diabetic retinopathy
Retinal detachment
Vitrectomy
Proliferative vitreoretinopathy
Maximum tolerated dose
Low molecular weight heparin
Diabetes mellitus
Medicine
Anatomy
open label
Ophthalmology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations